venBio Global Strategic Fund II L.P.'s Net Worth
$153 Million
Who is venBio Global Strategic Fund II L.P.?
venBio Global Strategic Fund II L.P. has an estimated net worth of $153 Million. This is based on reported shares across multiple companies, which include Checkmate Pharmaceuticals, Inc., ALX ONCOLOGY HOLDINGS INC, Akero Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Menlo Therapeutics Inc., and IMPEL NEUROPHARMA INC.
SEC CIK
venBio Global Strategic Fund II L.P.'s CIK is 0001634632
Past Insider Trading and Trends
2021 was venBio Global Strategic Fund II L.P.'s most active year for acquiring shares with 3 total transactions. venBio Global Strategic Fund II L.P.'s most active month to acquire stocks was the month of March. 2022 was venBio Global Strategic Fund II L.P.'s most active year for disposing of shares, totalling 20 transactions. venBio Global Strategic Fund II L.P.'s most active month to dispose stocks was the month of March. 2021 saw venBio Global Strategic Fund II L.P. paying a total of $6,750,000.00 for 2,861,248 shares, this is the most they've acquired in one year. In 2022 venBio Global Strategic Fund II L.P. cashed out on 1,517,444 shares for a total of $15,776,507.63, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Checkmate Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.75% | -131.65K |
$10.45 | -$1,375,564.42 | 2.16M |
May 13 - May 16
| |||
Form 4
| -6.57% | -160.90K |
$10.39 | -$1,671,823.84 | 2.29M |
May 10 - May 12
| |||
Form 4
| -3.42% | -86.68K |
$10.37 | -$898,920.56 | 2.45M |
May 5 - May 9
| |||
Form 4
| -9.65% | -270.68K |
$10.38 | -$2,809,332.35 | 2.54M |
May 2 - May 4
| |||
Form 4
| -6.34% | -190.03K |
$10.38 | -$1,972,578.78 | 2.81M |
Apr 27 - Apr 29
| |||
Form 4
| -4.15% | -129.78K |
$10.39 | -$1,347,796.50 | 3M |
Apr 22 - Apr 26
| |||
Form 4
| -14.91% | -547.73K |
$10.41 | -$5,700,491.17 | 3.13M |
Apr 19 - Apr 21
| |||
Form 4
|
∞
| 3.67M |
$15.00 |
—
| 3.67M |
Aug 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Akero Therapeutics, Inc. (AKRO) Snapshot price: $26.41
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -3.70% | -116.47K |
$34.40 | -$4,006,536.85 | 3.03M |
Jul 1 - Jul 6
| |||
Form 4
| -1.44% | -45.95K |
$23.76 | -$1,091,607.66 | 3.15M |
Mar 4 - Mar 6
| |||
Form 4
| -0.68% | -21.80K |
$22.63 | -$493,310.23 | 3.2M |
Feb 28 - Mar 3
| |||
Form 4
| -0.18% | -5.90K |
$22.80 | -$134,635.10 | 3.23M |
Feb 25 - Feb 27
| |||
Form 4
| -0.15% | -10.03K |
$27.07 | -$271,399.19 | 6.46M |
Feb 10 - Feb 12
| |||
Form 4
| -0.19% | -6.10K |
$27.03 | -$164,954.76 | 3.23M |
Feb 6
| |||
Form 4
| -2.48% | -82.34K |
$25.77 | -$2,121,726.32 | 3.24M |
Feb 4 - Feb 5
| |||
Form 4
| -12.95% | -494.00K |
$20.23 | -$9,993,620.00 | 3.32M |
Jan 13
| |||
Form 4
| -0.41% | -15.68K |
$19.86 | -$311,354.63 | 3.82M |
Jan 8
| |||
Form 4
| -1.88% | -73.22K |
$19.86 | -$1,454,529.98 | 3.83M |
Jan 6 - Jan 7
| |||
Form 4
| -0.90% | -35.50K |
$19.71 | -$699,721.20 | 3.91M |
Jan 2 - Jan 3
| |||
Form 4
| -0.36% | -14.32K |
$23.96 | -$343,258.90 | 3.94M |
Dec 31
| |||
Form 4
|
∞
| 3.95M |
$16.00 |
—
| 3.95M |
Jun 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
IMPEL NEUROPHARMA INC (IMPL) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.76M |
$15.00 |
—
| 2.76M |
Apr 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ALX ONCOLOGY HOLDINGS INC (ALXO) Snapshot price: $1.91
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +584.38% | 7.97M |
$19.00 |
—
| 9.34M |
Jul 16 - Jul 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Apellis Pharmaceuticals, Inc. (APLS) Snapshot price: $41.65
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.58M |
$14.00 |
—
| 3.58M |
Nov 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||